BioSpace News Archive

Grant from Leading Duchenne Organization Will Help Ensure Both Safety & Efficacy of Potential Therapy as Part of Their Gene Therapy Initiative [04-June-2019] HACKENSACK, N.J. , June 4, 2019 /PRNewswire/ -- Parent Project Muscular Dystrophy (PPMD) , a nonprofit organization leading the fight to end Duchenne muscular dystrophy (Duchenne) , announced that Drs. Mel

The Personal Connected Health Alliance, a HIMSS innovation company, announced that the 2019 Connected Health Conference will return to Boston, October 16-18.

CQDM is pleased to announce that following their recent enrollment in the consortium, Amgen and Takeda will be joining the syndicate of pharma companies to fund the Quantum Leap project recently launched by Feldan Therapeutics (Feldan)

Healthcare supply chain management company selects Sage for healthcare marketing expertise

Cesca Therapeutics Inc. (Nasdaq: KOOL), a market leader in automated cell processing and autologous cell therapies for regenerative medicine, today announced that it has amended its Sixth Amended and Restated Certificate of Incorporation to reflect a 1-for-10 reverse stock split of its common stock, which will be effective at 5:00 p.m. Pacific Time on June 4, 2019.

HeartCare Imaging (HCI) and the George Washington Medical Faculty Associates (GW MFA), Washington DC’s largest independent physician practice with more than 750 providers, are announcing a new initiative to improve patient care nationwide by providing specialty clinical care through telemedicine.

Zavation, an employee-owned medical device company that designs, develops, manufactures and distributes medical device products, announced today that it has received 510(k) clearance from the US Food and Drug Administration (FDA) to market the Ti3Z Interbody System (TLIF, T-PLIF, and PLIF).

An overwhelming 88 percent of U.S. hospital and health system executives agree that their organizations are vulnerable to consumer-friendly offerings from non-hospital competitors, such as Optum, CVS Health, and Amazon

Novartis announced today results from the landmark COMBI-d and COMBI-v clinical trials, concluding that first-line treatment with Tafinlar (dabrafenib) and Mekinist (trametinib) offers both overall and progression-free long-term survival benefits to patients with unresectable or metastatic BRAF-mutation positive melanoma

Reaction Biology Corporation (“RBC”), a leading contract research organization providing early stage drug discovery services, announced that it has received a subcontract from Leidos Biomedical Research, Inc., which operates the Frederick National Laboratory for Cancer Research for the National Cancer Institute